key: cord-0254305-2si7l1lz
authors: Lane, Thomas R.; Ekins, Sean
title: Towards the Target: Tilorone, Quinacrine and Pyronaridine Bind to Ebola Virus Glycoprotein
date: 2020-05-28
journal: bioRxiv
DOI: 10.1101/2020.05.26.118182
sha: a716da17a71bf61184da0ab59ec8a3ebaa1937db
doc_id: 254305
cord_uid: 2si7l1lz

Pyronaridine, tilorone and quinacrine were recently identified by a machine learning model and demonstrated in vitro and in vivo activity against Ebola virus (EBOV) and represent viable candidates for drug repurposing. These drugs were docked into the crystal structure of the ebola glycoprotein and then experimentally validated in vitro to generate Kd values for tilorone (0.73 μM) pyronaridine (7.34 μM), and quinacrine (7.55 μM). These are more potent than the previously reported toremifene (16 μM).

generate Kd values for tilorone (0.73 M) pyronaridine (7.34 M), and quinacrine (7.55 23 M). These are more potent than the previously reported toremifene (16 M). Organization (1). While there is an approved vaccine for prevention of EBOV disease 39

(2) we have no approved antivirals to treat patients although there are several same site at the tunnel entrance to the glycoprotein, destabilizing it and resulting in 48 release of GP2, thus preventing fusion between virus and endosome (9). Several other 49 research groups have identified small molecules that inhibit glycoprotein, suggesting a 50 wide array of molecules may bind (11-15). Others have used computational approaches 51 to perform virtual screens to identify inhibitors of GP2 (16). Recent efforts to identify 52 small molecules drugs for EBOV have included using computational methods in the 53 form of a Bayesian machine learning (ML) approach trained with EBOV inhibitors (17, 54 18 ). This ML model enabled a virtual screen and selection of three compounds, tilorone, 55 quinacrine and pyronaridine tetraphosphate (19). All these drugs inhibited EBOV in vitro 56 and in vivo in the mouse-adapted EBOV (ma-EBOV) efficacy model (20) (21) (22) (23) . 57

Pyronaridine tetraphosphate also demonstrated significant activity in the guinea pig 58 adapted model of EBOV infection (24) and is currently used as an antimalarial in 59 combination with artesunate (Pyramax®). Most recently pyronaridine was shown to be a 60 potent lysosomotropic agent while artesunate which is also active against EBOV in vitro 61

was not (25). Combining these two drugs had an additive effect on inhibiting EBOV exchanged into 10 mM MES, pH 5.0, 150 mM NaCl, 170 mM sodium malonate at pH 89 5.2 (MST buffer), which is similar to a buffer previously shown to be appropriate for 90 EBOV GP (10), and then diluted to a final concentration of 1 µM. For each experimental 91 compound 16 independent stocks were made in DMSO using 2-fold serial dilution (10 92 mM initial concentration). The MST buffer used for a final dilution prior to MST was 93 supplemented with 0.05% Tween 20 and 10 mM BME. The protein was diluted to 2. to pyronaridine with which it is used in combination as the drug Pyramax TM for malaria. 129

The lack of inhibition of glycoprotein by artesunate provides further confirmation of this. against EBOV as well as excellent in vitro absorption, distribution, metabolism and 132 excretion (ADME) properties and a very long half-life across mice and humans (21). It 133 also has statistically significant in vivo efficacy in mice and guinea pigs infected with 134 EBOV (24). While the mechanism to date was unclear, it has been shown to inhibit 135 lysostracker suggesting a lysosomotropic effect (25). When this is coupled with the 136 potential to bind to glycoprotein this dual mechanism will likely prevent EBOV entry. 137

Similarly, quinacrine, is a small-molecule, orally bioavailable drug which has also been 138 used clinically as an antimalarial. This also has very favorable ADME properties (apart to how these molecules target EBOV glycoprotein as well as being lysosomotropic, 149 enabling their blocking of viral entry. This information may aid in structure guided 150 modification of these compounds and future X-ray crystallography. Such mechanistic 151 insights may aid drug discovery for other viruses (e.g. SARS-CoV-2). To date tilorone and pyronaridine points to them sharing a common target or mechanism for the 157 inhibition of EBOV (20-22, 24, 25, 28) . It would also appear they all block entry, are 158 lysosomotropic and now are identified to bind to the glycoprotein. Shedding further light 159 on how these molecules work in vitro may provide further justification for clinically 160 repurposing these compounds. 161

We would like to sincerely thank Dr Peter Madrid 

First FDA-approved vaccine for the prevention of Ebola virus 185 disease, marking a critical milestone in public health preparedness and 186 response

Reversion of advanced Ebola virus 193 disease in nonhuman primates with ZMapp

Safety, pharmacokinetics, 203 and immunogenicity of a co-formulated cocktail of three human monoclonal 204 antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, 205 first-in-human phase 1 study

A Randomized, Controlled Trial of Ebola Virus Disease 215

Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine 245

Discovery, 247 synthesis, and biological evaluation of a novel group of selective inhibitors of 248 filoviral entry

Structures of

Antipsychotic Drugs

Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry

Machine learning models identify molecules active against Ebola virus in vitro

Repurposing 268

Quinacrine Against Ebola Virus Infection In vivo

Repurposing The Antimalarial Pyronaridine 272

Efficacy of Tilorone 276

Tilorone: a Broad-Spectrum Antiviral 279 Invented in the USA and Commercialized in Russia and beyond

Repurposing Pyramax® for the 287 Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine 288 and Non-Lysosomotropic Artesunate

Tilorone: A Broad-Spectrum Antiviral For Emerging 291

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-294 approved drugs.Antimicrob Agents Chemother In press

Ebola Virus Bayesian Machine Learning 297